Evidence map›Paper›PMID 37437211›Full record

ArticleBrain : a journal of neurology2023

Models of KPTN-related disorder implicate mTOR signalling in cognitive and overgrowth phenotypes.

Maria O Levitin, Lettie E Rawlins, Gabriela Sanchez-Andrade, Osama A Arshad, Stephan C Collins, Stephen J Sawiak, Phillip H Iffland, Malin H L Andersson, Caleb Bupp, Emma L Cambridge and 34 more

Open access · hybridAbstract read
In one paragraph

Article in Brain : a journal of neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

44 authors at 16 institutions in 6 countries.

Maria O LevitinWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
Lettie E RawlinsRILD Wellcome Wolfson Medical Research Centre, University of Exeter, Exeter EX2 5DW, UK.ORCID 0000-0002-6764-253X
Gabriela Sanchez-AndradeWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
Osama A ArshadWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
Stephan C CollinsINSERM Unit 1231, Université de Bourgogne Franche-Comté, Dijon 21078, France.
Stephen J SawiakBehavioural and Clinical Neuroscience Institute, University of Cambridge, Cambridge CB2 3EB, UK.
Phillip H IfflandDepartment of Neurology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Malin H L AnderssonWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
Caleb BuppSpectrum Health, Helen DeVos Children's Hospital, Grand Rapids, MI 49503, USA.ORCID 0000-0003-4255-0396
Emma L CambridgeWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
Eve L CoomberWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
Ian EllisDepartment of Clinical Genetics, Alder Hey Children's Hospital, Liverpool L14 5AB, UK.
Johanna C HerkertDepartment of Genetics, University Medical Centre, University of Groningen, Groningen 9713 GZ, The Netherlands.
Holly IronfieldWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
Logan JoryHaven Clinical Psychology Practice Ltd, Bude, Cornwall EX23 9HP, UK.
Perrine F KretzIGBMC, UMR7104, INSERM, Illkirch 67404, France.
Sarina G KantDepartment of Clinical Genetics, Erasmus MC, University Medical Center Rotterdam, Rotterdam 3015 GD, The Netherlands.
Alexandra NeaversonWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
Esther NibbelingLaboratory for Diagnostic Genome Analysis, Department of Clinical Genetics, Leiden University Medical Center, Leiden 3015 GD, The Netherlands.
Christine RowleyWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
Emily ReltonWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
Mark SandersonWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
Ethan M ScottNew Leaf Center, Clinic for Special Children, Mount Eaton, OH 44659, USA.
Helen StewartOxford Centre for Genomic Medicine, Oxford University Hospitals NHS Trust, Oxford OX3 7HE, UK.
Andrew Y ShuenLondon Health Sciences Centre, London, ON N6A 5W9, Canada.
John SchreiberDepartment of Neurology, Children's National Medical Center, Washington DC 20007, USA.
Liz TuckWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
James TonksHaven Clinical Psychology Practice Ltd, Bude, Cornwall EX23 9HP, UK.
Thorkild TerkelsenDepartment of Clinical Genetics, Aarhus University Hospital, Aarhus DK-8200, Denmark.
Conny van Ravenswaaij-ArtsDepartment of Genetics, University Medical Centre, University of Groningen, Groningen 9713 GZ, The Netherlands.
Pradeep VasudevanDepartment of Clinical Genetics, University Hospitals of Leicester, Leicester Royal Infirmary, Leicester LE1 7RH, UK.
Olivia WengerNew Leaf Center, Clinic for Special Children, Mount Eaton, OH 44659, USA.
Michael WrightInstitute of Human Genetics, International Centre for Life, Newcastle upon Tyne NE1 7RU, UK.
Andrew DayWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
Adam HunterWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
Minal PatelWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
Christopher J LelliottWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
Peter B CrinoDepartment of Neurology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Binnaz YalcinINSERM Unit 1231, Université de Bourgogne Franche-Comté, Dijon 21078, France.ORCID 0000-0002-1924-6807
Andrew H CrosbyRILD Wellcome Wolfson Medical Research Centre, University of Exeter, Exeter EX2 5DW, UK.ORCID 0000-0003-3667-9054
Emma L BapleRILD Wellcome Wolfson Medical Research Centre, University of Exeter, Exeter EX2 5DW, UK.ORCID 0000-0002-6637-3411
Darren W LoganWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
Matthew E HurlesWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.
Sebastian S GeretyWellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge CB10 1SA, UK.ORCID 0000-0002-6126-5040
Wellcome Sanger Institute · GBUniversity of Cambridge · GBInserm · FRUniversity of Exeter · GBClinic for Special Children · USLeiden University Medical Center · NLUniversity of Groningen · NLUniversity of Maryland, Baltimore · USAarhus University Hospital · DKCentre for Life · GBChildren's National · USLeicester Royal Infirmary · GBOxford University Hospitals NHS Trust · GBSpectrum Health · USUniversity of Liverpool · GBWestern University · CA

Funding

KPTN Loss and Megalencephaly: mTOR Activation as Therapeutic TargetR37NS125632 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI Peter B Crino · 2022 to 2026
$1.7M
Department of HealthMedical Research CouncilNINDS NIH HHS R37 NS125632Wellcome TrustWellcome Trust 108413/A/15/DWellcome Trust 206194Wellcome Trust WT098051
6 · The paper itself

Abstract

KPTN-related disorder is an autosomal recessive disorder associated with germline variants in KPTN (previously known as kaptin), a component of the mTOR regulatory complex KICSTOR. To gain further insights into the pathogenesis of KPTN-related disorder, we analysed mouse knockout and human stem cell KPTN loss-of-function models. Kptn -/- mice display many of the key KPTN-related disorder phenotypes, including brain overgrowth, behavioural abnormalities, and cognitive deficits. By assessment of affected individuals, we have identified widespread cognitive deficits (n = 6) and postnatal onset of brain overgrowth (n = 19). By analysing head size data from their parents (n = 24), we have identified a previously unrecognized KPTN dosage-sensitivity, resulting in increased head circumference in heterozygous carriers of pathogenic KPTN variants. Molecular and structural analysis of Kptn-/- mice revealed pathological changes, including differences in brain size, shape and cell numbers primarily due to abnormal postnatal brain development. Both the mouse and differentiated induced pluripotent stem cell models of the disorder display transcriptional and biochemical evidence for altered mTOR pathway signalling, supporting the role of KPTN in regulating mTORC1. By treatment in our KPTN mouse model, we found that the increased mTOR signalling downstream of KPTN is rapamycin sensitive, highlighting possible therapeutic avenues with currently available mTOR inhibitors. These findings place KPTN-related disorder in the broader group of mTORC1-related disorders affecting brain structure, cognitive function and network integrity.

Indexed as

Signal TransductionTOR Serine-Threonine KinasesAnimalsBrainCognitionHumansMechanistic Target of Rapamycin Complex 1MiceMicrofilament ProteinsKPTN protein, humanMechanistic Target of Rapamycin Complex 1Microfilament ProteinsTOR Serine-Threonine Kinasesanimal modeliPSCmacrocephalymTORneurodevelopmental disordersrecessive

Identifiers

PMID37437211
PMCPMC10629792
OpenAlexW4384024096

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.